Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of AB (Nab-Paclitaxel [Abraxane?], Bevacizumab) Versus Ipilimumab for Therapy of Unresectable Stage IV Metastatic Malignant Melanoma

NCT02158520 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT02158520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02158520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of AB (Nab-Paclitaxel [Abraxane?], Bevacizumab) Versus Ipilimumab for Therapy of Unresectable Stage IV Metastatic Malignant Melanoma
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Completed
Start date
October 18, 2013
Completion date
October 30, 2019
Enrollment
24 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma, mucosal melanoma, stage iv cutaneous melanoma ajcc v6 and v7, stage iv uveal melanoma ajcc v7, unresectable melanoma